ClinicalTrials.gg
CompletedNCT06719310Updated Aug 14, 2026

Phase Ib/IIa Clinical Study of ACC017 Tablets

A Phase 1/2 interventional study of ACC017+FTC/TAF and Placebo in Infection, Human Immunodeficiency Virus, sponsored by Jiangsu Aidea Pharmaceutical Group Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-14.

Sponsored by Jiangsu Aidea Pharmaceutical Group Co., Ltd. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

ACC017 is an integrase inhibitor that will be evaluated for the treatment of HIV infection. This phase Ib/IIa, randomized, double-blind, parallel, dose ranging, placebo-controlled 'proof of concept' study is designed to evaluate the safety, tolerability, pharmacokinetics and antiviral effect of ACC017 monotherapy and combined with FTC/TAF by sequency versus placebo in treatment-naïve HIV-1 infected adults. This study includes two stages, stage one is a single dose escalation, and all subjects will be co-administrated with FTC/TAF at 200 mg/25 mg on stage two. The study consists of a screening visit, baseline period, monotherapy period, and combination therapy period. Total 36 subjects will be randomized in a 5:1 ratio to receive one of three doses of ACC017 or placebo lasting for 10 days for monotherapy followed by 18 days for combination therapy.

Read the detailed description

This phase Ib/IIa study in HIV-infected antiretroviral naive adult subjects is conducted to evaluate the safety, tolerability, pharmacokinetics and antiviral effect of ACC017 tablet as monotherapy/combination with NRTIs and to explore the recommended dose for the future pivotal clinical trial of ACC017. The study will be conducted as two stages. Stage one will includes a dose-ranging evaluation of ACC017 5mg, 40mg and 80mg once daily compared to placebo on the basis of safety, tolerability, pharmacokinetics and antiviral activity. Subjects will be randomized in a 5:1 ratio to receive one of three doses of ACC017 or placebo. Each subject will receive ACC017 tablet as monotherapy for 10 days and then followed by a combination with NRTIs for 18 days. In monotherapy, the enrolment into the next higher dose group will commence only when investigator and sponsor both agree that ACC017 is safe and well tolerated at a given dose. Stage two is open and subjects will continue to take ACC017 at the dose given on stage one in combination with FTC/TAF tablet at 200 mg/25 mg once daily for 18 days. Subjects randomized to receive placebo in stage one will receive the equivalent dose of ACC017 combined with FTC/TAF.

02

Conditions studied

  • Infection, Human Immunodeficiency Virus
03

In context

Infections

2,096 studies on the registry are indexed under Infections; 364 are open to participants now.

This study's enrollment of 36 is below the median of 113 across 1,305 interventional studies indexed under Infections.

Browse Infections studies →

Lead sponsor

Jiangsu Aidea Pharmaceutical Group Co., Ltd. is the lead sponsor of 7 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willing to sign the and agree to comply to the study procedures and requests
  2. Age range between 18 and 65 years old at the time of signing informed consent, regardless of gender
  3. Body weight ≥40 kg, and range between 18.5\~29.9 kg/m2 (including the borderline) at screening
  4. Documented HIIV-1 infection before screening, and never receive any antiHIV-1 drugs or vaccines after the diagnosis of -1 infection
  5. Agree not to use any antiviral drugs other than those allowed by protocol during study period.
  6. Plasma HIV RNA≥5000 copies/mL at screening;
  7. of >200 cells/μL

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of acute infection at screening or unstable AIDS related disease within 4 weeks prior to screening.
  2. Had PrEP and/or PEP treatment within 1 month prior to screening.
  3. Had uncontrolled severe disease judged by investigator, such as systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg, class III or IV or fasting glucose ≥7.0 mmol/L.
  4. History of serious allergy to drugs (such as aspirin or cephalosporin antibiotics) or their ingredients' or food (a fast, life-threatening systemic allergic reaction), or allergic disease requiring drug control (such as asthma, urticaria, atopic dermatitis [eczema].).
  5. Any major gastrointestinal surgery (except uncomplicated appendectomy or cholecystectomy) or any surgery affecting drug absorption, distribution, metabolism and excretion within 6 months before screening; or possible elective surgery during the trial as judged by the investigator.
  6. History of cancer(except cervical carcinoma in situ, or cutaneous basal cell carcinoma, squamous cell carcinoma, and/or carcinoma in situ [Bowen's disease] that received radical surgery or treatment) within 5 years prior to screening.
  7. \<90 g/L, or WBC count \<1.5×109/L, or ANC count \<0.6×109/L, or count \<50×109/L at screening.
  8. and/or AST > 2.5 times (ULN), or > 1.5 × ULN, or DBIL > ULN, or ALB \<30 g/L at screening.
  9. SCr > 1.3 ×ULN, or Ccr \<60 mL/min ( formula) at screening,
  10. Blood amylase or lipase >1.5 ×ULN
  11. Subjects with a positive for or anti-, or those with anti-Tp positive who need to be treated required by investigator or their treatment period \<7 days at screening.
  12. Average smoked cigarettes more than 5 a day within 3 months prior to screening or unwilling to stop using any tobacco products during hospitalization.
  13. Drinking more than 14 units per week within 3 months prior to screening ( 1 unit of alcohol is equivalent to 5% beer, 45 mL of 40% alcohol, 150mL of 12% alcohol), or a positive alcohol breath test at a screening or baseline visit, or unwilling to stop drink any alcohol-containing product during hospitalization.
  14. Excessive consumption of tea, coffee or caffeine ( more than 8 cups per day on average, 1 cup of 250 mL) or unwilling to stop drinking tea, coffee, or caffeine during hospitalization.
  15. Having taken pitaya, mango, grapefruit, star fruit or any preparations made from them, or food/drinking containing xanthine, caffeine or alcohol (e.g.chocolate, tea, coffee, cola and cocoa) or others that will affect the absorption, distribution, metabolism, excretion of drugs, within 48 hours prior to the first dose of experimental drugs, or unwilling to stop taking them during hospitalization.
  16. Use of any potent or moderate inhibitors (e.g. clarithromycin, thalimycin, ketocomazole, ketoconazole, itraconazole, and CYP3A4) or potent CYP3A4 inducers (e.g. rifampin, efavirenz,carbamazepine, phenobarbitone, phenytoin) within 14 days prior to the first dose of experimental drugs or within 5 half-lives(whichever is longer).
  17. Use of any potent or moderate UGT1A inhibitors (e.g. silybin. Ritonavir) or potent UGT1A1 inducers (e.g. rifampin, carbamazepine) within 14 days prior to the first dose of experimental drugs or within 5 half-lives (whichever is longer).
  18. Use of any prescription drug, nonprescription drug, Chinese traditional herbs within 14 days prior to the first dose of experimental drugs or within 5 half-lives (whichever is longer).
  19. History of drug dependence (social, psychological and physical impairment due to excessive, impropriate or addictive use of substances for any non-medical reason) within 5 years prior to screening, or positive urine drug screen at screening or baseline.
  20. Intolerance to venipuncture, or have a history of halo acupuncture or blood sickness, or have donated blood including component blood or have had substantial blood loss (more than 400 mL) or have received a blood transfusion within 3 months prior to screening, or plan to donate blood during study.
  21. Have special dietary requirements at screening, or refuse to accept a standard diet.
  22. Have participated in or are participating in another drug or medical device clinical study within 3 months prior to screening.
  23. Women who are pregnant or breastfeeding or who have a positive blood pregnancy test at screening.
  24. Have a birth plan (including conception, eggs or sperm donation) within 1 month before signing form until 3 months after last dose of experimental drugs or refuse to use effective any methods.
  25. Other conditions exist that, in the judgement of the investigator, make participation in this study unsuitable.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Participant group 1

    Stage one: ACC017 (Dose 1) Stage two: ACC017 (Dose 1)+FTC/TAF (200mg/25mg) QD

    Drug: ACC017+FTC/TAF

  • Experimental
    Participant group 2

    Stage one: ACC017 (Dose 2) Stage two: ACC017 (Dose 2)+FTC/TAF (200mg/25mg) QD

    Drug: ACC017+FTC/TAF

  • Experimental
    Participant group 3

    Stage one: ACC017 (Dose 3) Stage two: ACC017 (Dose 3)+FTC/TAF (200mg/25mg) QD

    Drug: ACC017+FTC/TAF

  • Placebo comparator
    Participant group 4

    Stage one: Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Report the incidence, severity and seriousness of adverse events, and the relationship between drug and AE

    Report the incidence, severity and seriousness of adverse events, and the relationship between drug and AE

    Time frame: Day 1- Day 11

  2. HIV-1 RNA viral load change from baseline

    HIV-1 RNA viral load change from baseline

    Time frame: Day 11

  3. Proportion of patients with HIV-1 RNA viral load <50 copies/mL

    Proportion of patients with HIV-1 RNA viral load \<50 copies/mL

    Time frame: Day 29

  4. Pharmacokinetics parameter: Cτ,ss

    Cτ,ss is defined as the steady-state plasma drug concentration at the end of the dosing interval after the last administration of a given dose on the monotherapy and combination therapy periods.

    Time frame: Day 10, Day 29

  5. Pharmacokinetics parameter: Cmin,ss

    Cmin,ss is defined as the minimum steady-state plasma drug concentration after the last dose of monotherapy.

    Time frame: Day 10

  6. Pharmacokinetics parameter: Cmax,ss

    Cmax,ss is defined as the maximum steady-state plasma drug concentration after the last dose of monotherapy.

    Time frame: Day 10

  7. Pharmacokinetics parameter: AUC0-τ,ss

    AUC0-τ,ss is defined as the steady-state area under the plasma concentration-time curve from time zero to the any dosing interval of monotherapy.

    Time frame: Day 1- Day 10

  8. Pharmacokinetics parameter: Tmax,ss

    Tmax,ss is defined as the time to reach steady-state maximum plasma concentration during monotherapy period.

    Time frame: Day 1-Day 10

  9. Pharmacokinetics parameter: MRT0-τ,ss

    MRT0-τ,ss is defined as the steady-state mean residence time from time zero to any dosing interval of monotherapy.

    Time frame: Day 1-Day 10

Secondary outcomes

  1. Changes over time in temperature of vital signs

    Temperature in degree Celsius.

    Time frame: Day 1-Day 29

  2. Changes over time in pulse of vital signs

    Pulse in beat per minute.

    Time frame: Day 1-Day 29

  3. Changes over time in systolic and diastolic blood pressure of vital signs

    Systolic and diastolic blood pressure in millimeters (mm) of mercury (Hg).

    Time frame: Day 1-Day 29

  4. Changes over time in respiratory rate of vital signs

    Respiratory rate in breaths per minute.

    Time frame: Day 1-Day 29

  5. Changes over time in heart rate as measured by electrocardiogram(ECG)

    Heart rate in beat per minute.

    Time frame: Day 1-Day 29

  6. Changes over time in PR interval as measured by ECG

    PR interval is measured by ECG.

    Time frame: Day 1-Day 29

  7. Changes over time in QRS duration

    QRS duration is measured by ECG.

    Time frame: Day 1-Day 29

  8. Changes over time in QTc interval

    QTc interval is measured by ECG.

    Time frame: Day 1-Day 29

  9. Changes over time in weight

    Weight is in kilograms.

    Time frame: Day 1-Day 29

  10. Pharmacokinetics parameters: Cmax

    The maximum drug concentration following the first dose of monotherapy.

    Time frame: Day 1-Day 2

  11. Pharmacokinetics parameters: Cτ

    The drug concentration on the end of the first dosing interval of monotherapy.

    Time frame: Day 2

  12. Pharmacokinetics parameters: AUC0-τ

    AUC0-τ is defined as the area under the plasma concentration-time curve from time zero to the first dosing interval of monotherapy.

    Time frame: Day 2

  13. Pharmacokinetics parameters: Tmax

    Time to reach the maximum drug concentration after the first dose of monotherapy.

    Time frame: Day 1- Day 2

  14. Pharmacokinetics parameters: MRT0-τ

    MRT0-τ is defined as the steady-state mean residence time from time zero to the first dosing interval of monotherapy.

    Time frame: Day 1- Day 2

  15. Report the incidence, severity and seriousness of adverse events, and the relationship between drug and AE

    Report the incidence, severity and seriousness of adverse events, and the relationship between drug and AE

    Time frame: Day 11-Day 29

  16. HIV-1 RNA viral load changes from baseline over time

    HIV-1 RNA viral load changes from baseline over time

    Time frame: Day 2-Day 4, Day 8-Day 11, Day 21, Day 29

  17. Proportion of patients with HIV-1 RNA viral load <50 copies/mL

    Proportion of patients with HIV-1 RNA viral load \<50 copies/mL

    Time frame: Day 11

  18. Proportion of patients with HIV-1 RNA viral load <200 copies/mL

    Proportion of patients with HIV-1 RNA viral load \<200 copies/mL

    Time frame: Day 11, Day 29

  19. The proportion of patients with HIV-1 RNA viral load <400 copies/mL

    The proportion of patients with HIV-1 RNA viral load \<400 copies/mL

    Time frame: Day 11, Day 29

  20. Changes in viral load from baseline to HIV-1 RNA viral load at nadir

    Changes in viral load from baseline to HIV-1 RNA viral load at nadir

    Time frame: Day 11

  21. The proportion of nadir HIV-1 RNA <50 copies/mL

    The proportion of nadir HIV-1 RNA \<50 copies/mL

    Time frame: Day 11

07

Study locations

1 site
  • Beijing Ditan Hospital, Capital Medical University
    Beijing, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2024 to primary completion in Apr 2025, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2024
First posted
Dec 5, 2024
StartActual
Aug 28, 2024
Primary completionActual
Apr 28, 2025
CompletionActual
Apr 28, 2025
Last update
Aug 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06719310
Collaborators
Chengdu Aidea Pharmaceutical Technology Co., Ltd
Responsible party
Sponsor
First posted
Dec 5, 2024
Start date
Aug 28, 2024
Primary completion
Apr 28, 2025
Completion
Apr 28, 2025
Last update
Aug 14, 2026

Study contacts

Zhang Fujie, M.D., Ph.D.
principal investigator · Beijing Ditan Hospital
Hu C Ying, Ph.D.
principal investigator · Beijing Ditan Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: ACC017 · Emtricitabine · Tenofovir alafenamide

Start the discussion